FDA clears phase 2b study of LSD treatment for generalized anxiety
Clinical-stage biopharmaceutical company Mind Medicine Inc. announced the FDA cleared its investigational new drug application to proceed with a phase 2b dose-optimization of MM-120 for treating generalized anxiety disorder. The treatment is a pharmacologically optimized form of LSD in development for generalized anxiety disorders and other brain-based disorders, the company said in a press